Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. Submits Information Package to FDA

Published in Medical Letter on the CDC and FDA, January 11th, 2009

Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has filed a response to the FDA’s request for information and that the filing also includes a synopsis of the company’s revised protocol for a Phase II dose escalation clinical trial of Oxycyte® in Traumatic Brain Injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The company also announced that it has initiated safety and toxicity trials for the first Oxycyte wound-treatment indication.

In action items following the company’s meeting with the FDA on Oct. 22, 2008, the agency requested further information and data about thrombocytopenia – low...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2009-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database